Table 4.
Changes in the responders and non- responder following 24 weeks treatment
| Variables |
Responder group (n = 23) |
Non-responder group (n = 6) |
||
|---|---|---|---|---|
| Baseline | 24 weeks | Baseline | 24 weeks | |
| Body weight (kg) |
66.8 ± 16.3 |
67.3 ± 17.4 |
62.4 ± 14.8* |
64.3 ± 15.9 |
| Waist Circumference (cm) |
97.6 ± 12.2 |
98.0 ± 12.1 |
84.6 ± 85** |
85.9 ± 8.4 |
| Total insulin dose (units/day) |
71.3 ± 14.9 |
32.1 ± 14.0 |
59.8 ± 12.9 ** |
54.5 ± 14.7## |
| HbA1c (%) |
9.5 ± 1.2 |
7.8 ± 1.1 |
8.6 ± 1.3* |
8.4 ± 1.1## |
| FBG (mmol/L) |
12.0 ± 2.7 |
7.4 ± 1.4 |
9.8 ± 2.1* |
9.2 ± 1.5## |
| P2BG (mmol/L) |
16.7 ± 4.8 |
9.8 ± 2.4 |
16.3 ± 4.2 |
15.8 ± 4.2## |
| HMW adiponectin (ug/ml) | 2.89 ± 1.54 | 5.79 ± 1.58 | 4.74 ± 1.46** | 5.11 ± 1.52## |
Normally distributed data expressed as mean ± standard deviation and non-normally distributed data expressed as median or as numbers and percentages. Non-normally distributed data were logtransformed for use with parametric statistics. HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; HMW: high-molecular weight; Data are mean ± SD. *p < 0.05 and **P <0.01 for responder vs. non-responder at baseline; #p<0.05 and ##p<0.01 for absolute changes in responder vs. non-responder following 24 weeks glimepiride treatment.